BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33518513)

  • 1. Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet.
    Bourgeois T; Jalil A; Thomas C; Magnani C; Le Guern N; Gautier T; Pais de Barros JP; Bergas V; Choubley H; Mazzeo L; Menegaut L; Josiane Lebrun L; Van Dongen K; Xolin M; Jourdan T; Buch C; Labbé J; Saas P; Lagrost L; Masson D; Grober J
    J Lipid Res; 2021; 62():100013. PubMed ID: 33518513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LPCAT3 deficiency in hematopoietic cells alters cholesterol and phospholipid homeostasis and promotes atherosclerosis.
    Thomas C; Jalil A; Magnani C; Ishibashi M; Queré R; Bourgeois T; Bergas V; Ménégaut L; Patoli D; Le Guern N; Labbé J; Gautier T; de Barros JPP; Lagrost L; Masson D
    Atherosclerosis; 2018 Aug; 275():409-418. PubMed ID: 29866392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver x receptor regulates arachidonic acid distribution and eicosanoid release in human macrophages: a key role for lysophosphatidylcholine acyltransferase 3.
    Ishibashi M; Varin A; Filomenko R; Lopez T; Athias A; Gambert P; Blache D; Thomas C; Gautier T; Lagrost L; Masson D
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1171-9. PubMed ID: 23580142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficiency in lysophosphatidylcholine acyltransferase 3 reduces plasma levels of lipids by reducing lipid absorption in mice.
    Li Z; Jiang H; Ding T; Lou C; Bui HH; Kuo MS; Jiang XC
    Gastroenterology; 2015 Nov; 149(6):1519-29. PubMed ID: 26226572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage Lysophosphatidylcholine Acyltransferase 3 Deficiency-Mediated Inflammation Is Not Sufficient to Induce Atherosclerosis in a Mouse Model.
    Jiang H; Li Z; Huan C; Jiang XC
    Front Cardiovasc Med; 2018; 5():192. PubMed ID: 30705887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Intestine but Not Liver Lysophosphatidylcholine Acyltransferase 3 (Lpcat3) Deficiency Has a Dominant Effect on Plasma Lipid Metabolism.
    Kabir I; Li Z; Bui HH; Kuo MS; Gao G; Jiang XC
    J Biol Chem; 2016 Apr; 291(14):7651-60. PubMed ID: 26828064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion.
    Rong X; Wang B; Dunham MM; Hedde PN; Wong JS; Gratton E; Young SG; Ford DA; Tontonoz P
    Elife; 2015 Mar; 4():. PubMed ID: 25806685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Hepatic Lysophosphatidylcholine Acyltransferase 3 as a Novel Target Gene Regulated by Peroxisome Proliferator-activated Receptor δ.
    Singh AB; Liu J
    J Biol Chem; 2017 Jan; 292(3):884-897. PubMed ID: 27913621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LPCAT3/LPLAT12 deficiency in the liver ameliorates acetaminophen-induced acute liver injury.
    Inagaki NF; Nakanishi H; Ohto T; Shindou H; Shimizu T
    FASEB J; 2024 Jan; 38(1):e23328. PubMed ID: 38019192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Phospholipid Remodeling Modulates Insulin Sensitivity and Systemic Metabolism.
    Tian Y; Mehta K; Jellinek MJ; Sun H; Lu W; Shi R; Ingram K; Friedline RH; Kim JK; Kemper JK; Ford DA; Zhang K; Wang B
    Adv Sci (Weinh); 2023 Jun; 10(18):e2300416. PubMed ID: 37088778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis.
    Tian Y; Jellinek MJ; Mehta K; Seok SM; Kuo SH; Lu W; Shi R; Lee R; Lau GW; Kemper JK; Zhang K; Ford DA; Wang B
    Hepatology; 2024 Apr; 79(4):882-897. PubMed ID: 36999536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidylcholine Acyltransferase-3 Expression Is Associated with Atherosclerosis Progression.
    Tanaka H; Zaima N; Sasaki T; Yamamoto N; Inuzuka K; Yata T; Iwaki T; Umemura K; Sano H; Suzuki Y; Urano T; Setou M; Unno N
    J Vasc Res; 2017; 54(4):200-208. PubMed ID: 28683445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lpcat3 deficiency promotes palmitic acid-induced 3T3-L1 mature adipocyte inflammation through enhanced ROS generation.
    Hu J; Deng Y; Ding T; Dong J; Liang Y; Lou B
    Acta Biochim Biophys Sin (Shanghai); 2022 Nov; 55(1):117-130. PubMed ID: 36331295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting Phosphatidylcholine Remodeling in Adipose Tissue Increases Insulin Sensitivity.
    He M; Li Z; Tung VSK; Pan M; Han X; Evgrafov O; Jiang XC
    Diabetes; 2023 Nov; 72(11):1547-1559. PubMed ID: 37625119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty acid remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport.
    Hashidate-Yoshida T; Harayama T; Hishikawa D; Morimoto R; Hamano F; Tokuoka SM; Eto M; Tamura-Nakano M; Yanobu-Takanashi R; Mukumoto Y; Kiyonari H; Okamura T; Kita Y; Shindou H; Shimizu T
    Elife; 2015 Apr; 4():. PubMed ID: 25898003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting phospholipid remodeling pathway improves insulin resistance in diabetic mouse models.
    Tian Y; Lu W; Shi R; McGuffee R; Lee R; Ford DA; Wang B
    FASEB J; 2023 Nov; 37(11):e23251. PubMed ID: 37823674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase.
    Zhao Y; Chen YQ; Bonacci TM; Bredt DS; Li S; Bensch WR; Moller DE; Kowala M; Konrad RJ; Cao G
    J Biol Chem; 2008 Mar; 283(13):8258-65. PubMed ID: 18195019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease.
    Lagrost L; Masson D
    Curr Opin Lipidol; 2022 Jun; 33(3):193-198. PubMed ID: 35165232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review).
    Wang J; Li J; Fu Y; Zhu Y; Lin L; Li Y
    Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38362962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver-specific overexpression of LPCAT3 reduces postprandial hyperglycemia and improves lipoprotein metabolic profile in mice.
    Cash JG; Hui DY
    Nutr Diabetes; 2016 Apr; 6(4):e206. PubMed ID: 27110687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.